title: [Review of pharmacological interactions of oral anticancer drugs provided at pharmacy department].
abstract: OBJECTIVE
  To identify the pharmacologic interactions of oral anti-cancer drugs provided at an outpatient clinic.
  
  
  METHODS
  Anti-cancer drugs included in the Phamacotherapeutic Guideline of the Hospital were identified. A literature search was carried out on the pharmacologic interactions in MEDLINE® and EMBASE® (with the filer language English or Spanish, and the descriptors: "name of the anti-cancer drug" AND ("drug interactions" OR "pharmacokinetic")), Up-to-date®, MICROMEDEX® and the drug information sheet for the EMA and the FDA. Information was also gathered from the abstract presented to European and Spanish scientific meetings for the last 4 years. When an interaction was analyzed and had clinical relevance, the best pharmacotherapeutic interaction-free alternative was sought.
  
  
  RESULTS
  Twenty-three drugs were identified, of which Chlorambucil, Fludarabine, Lenalidomide, Melphalan, and Thalidomide were the active compounds with the lowest likelihood of producing a pharmacologic interaction. Tyrosine kinase inhibitors (particularly Erlotinib, Imatinib, Lapatinib, and Pazopanib) are the drugs with highest number of pharmacologic interactions described, many of them with severe clinical consequences, with increases and decreases of the plasma levels of anti-cancer drugs. The active compounds identified that may have pharmacologic interactions with anticancer drugs were mainly: Allopurinol, Amiodarone, Carbamazepine, Dabigatran, Digoxin, Spironolactone, Phenytoin, Itraconazol, Repaglinide, Silodosin, Tamoxifen, Verapamil, and Warfarin. Pharmacologic interactions through the cytochrome P450 1A2, 2D6, 2C8, 2C9, 3A4 were the most important for tyrosine kinase inhibitors. Other non-pharmacologic compounds, with an important potential of producing relevant pharmacologic interaction were immunomodulators (Echinacea extracts) and Hypericum perforatum.
  
  
  CONCLUSIONS
  Oral anticancer drugs have numerous pharmacologic interactions that should be monitored during pharmacotherapy. Given its position, the hospital pharmacist is the key professional for identifying and assessing the pharmacologic interactions or oral anticancer drugs that may have clinical consequences.
authors.affiliation: Servicio de Farmacia Hospitalaria. Hospital Juan Ramón Jiménez. Huelva. España.. esgfarmaceutico@gmail.com.
authors.forename: E
authors.initials: E
authors.lastname: Sánchez Gómez
authors.affiliation: Servicio de Farmacia Hospitalaria. Hospital Juan Ramón Jiménez. Huelva. España.. esgfarmaceutico@gmail.com.
authors.forename: Y
authors.initials: Y
authors.lastname: Arco Prados
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D010593:Pharmaceutical Services
chemical_list: D000970:Antineoplastic Agents